Canaccord Genuity Reiterates a 'Buy' on Avanir Pharmaceuticals (AVNR); Nuedexta Survey: Positive Dx and Prescribing Trends Suggest Continued Growth

Canaccord Genuity reiterates a 'Buy' on Avanir Pharmaceuticals (NASDAQ: AVNR) price target of $6.00.

Canaccord analyst, Ritu Baral, said, "Reiterate rating and price target on Nuedexta steady growth, ultimate commercial potential. Nuedexta is AVNR’s drug for pseudobulbar affect, emotional lability seen with stroke, traumatic brain injury and other neurodegenerative disorders. Launch has been modest but steady, and we see new positive trends in long-term care use. We estimate peak annual sales of $350M US and $300M EU."

For an analyst ratings summary and ratings history on Avanir Pharmaceuticals click here. For more ratings news on Avanir Pharmaceuticals click here.

Shares of Avanir Pharmaceuticals closed at $2.29 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• META to capture largest share of users, SNAP to benefit from ad budget shifts - Canaccord Genuity weighs in on TikTok ban
• First Cash Financial (FCFS) PT Lowered to $140 at TD Cowen
• TechnipFMC (FTI) PT Raised to $30 at BTIG